← All drugs
Drug · FAERS side-effect profile with label screen

Denosumab side effects: what 201,340 FDA adverse event reports show

Denosumab · Jubbonti · 1,223 reaction terms · 508,319 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

RANK Ligand Inhibitor

FDA label (Established Pharmacologic Class)

Brand names

Jubbonti

openFDA label

Who reports

201,340 reports · 54% serious · 25,732 with death outcome · 84% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture.

FDA label, Indications and Usage

What it is

Denosumab-bbdz is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand). Denosumab-bbdz has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.

FDA label, Description section

Boxed warning

SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE • Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled adverse reaction 3Labeled (related wording) 7Likely indication confounding 3Reporting / coding artifact 4Lab value / disease marker 5Not in label — unassessed 17
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,183 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Bone giant cell tumour307405.7
316.1–520.8ROR 406.3 · calibrated p 1e-12 ✓
81.8 EB05 74.4 · IC025 +6.0
3/3 methods agree
Not in label — unassessedserious n=307 · ♀ 54% (drug 84%) · 100% cliniciannot reported in cached trials
Exostosis of jaw289150.8
125.8–180.8ROR 151.0 · calibrated p 6e-9 ✓
61.1 EB05 55.4 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious n=206not reported in cached trials
Osteonecrosis of external auditory canal9095.4
71.6–127.2ROR 95.4 · calibrated p 3e-7 ✓
49.2 EB05 41.3 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=90 · 100% cliniciannot reported in cached trials
Atypical fracture22560.3
51.1–71.1ROR 60.3 · calibrated p 5e-6 ✓
38.1 EB05 34.1 · IC025 +4.9
3/3 methods agree
Labeled adverse reaction
exact term
serious n=224 · 100% cliniciannot reported in cached trials
Osteonecrosis of jaw (jawbone death)8,64555.2
53.7–56.6ROR 57.6 · calibrated p 5e-6 ✓
36.1 EB05 35.5 · IC025 +5.1
3/3 methods agree
Labeled — boxed warning
synonym match
serious PRR 38.3NCT00089791: 2/3,886 (0.1%) on Denosumab; 1/3,876 (0.0%) control (serious AE)
Atypical femur fracture88146.7
43.1–50.6ROR 46.9 · calibrated p 2e-5 ✓
32.3 EB05 30.6 · IC025 +4.9
3/3 methods agree
Labeled adverse reaction
exact term
serious n=879not reported in cached trials
Tooth resorption6344.8
33.3–60.3ROR 44.8 · calibrated p 4e-5 ✓
31.2 EB05 25.2 · IC025 +4.2
3/3 methods agree
Not in label — unassessed100% consumernot reported in cached trials
Dental implantation40934.7
31.0–38.8ROR 34.7 · calibrated p 1e-4 ✓
26.1 EB05 24.0 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=203not reported in cached trials
Oestrogen deficiency6934.6
26.3–45.5ROR 34.6 · calibrated p 2e-4 ✓
25.9 EB05 21.2 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=52 · 100% consumernot reported in cached trials
Artificial crown procedure11932.7
26.6–40.2ROR 32.7 · calibrated p 2e-4 ✓
24.9 EB05 21.4 · IC025 +4.2
3/3 methods agree
Reporting / coding artifact–not reported in cached trials
Pik3ca-activated mutation7530.9
23.9–40.0ROR 30.9 · calibrated p 3e-4 ✓
23.8 EB05 19.6 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=75 · 100% cliniciannot reported in cached trials
Dental restoration failure15127.4
22.9–32.8ROR 27.4 · calibrated p 5e-4 ✓
21.7 EB05 19.0 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=71not reported in cached trials
Bone density abnormal71724.3
22.4–26.3ROR 24.3 · calibrated p 8e-4 ✓
19.8 EB05 18.6 · IC025 +4.2
3/3 methods agree
Lab value / disease markerserious n=179not reported in cached trials
Blood parathyroid hormone increased55124.0
21.9–26.4ROR 24.1 · calibrated p 8e-4 ✓
19.6 EB05 18.3 · IC025 +4.1
3/3 methods agree
Lab value / disease markerserious n=333not reported in cached trials
Carbohydrate antigen 15-3 increased13822.9
19.0–27.5ROR 22.9 · calibrated p 0.001 ✓
18.8 EB05 16.3 · IC025 +3.9
3/3 methods agree
Lab value / disease markerserious n=137 · 100% cliniciannot reported in cached trials
Hypocalcaemia (low calcium)3,33822.2
21.4–23.1ROR 22.6 · calibrated p 0.001 ✓
18.4 EB05 17.9 · IC025 +4.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 14.7 · serious PRR 17.6 · ♀ 61% (drug 84%)NCT00089791: 1/3,876 (0.0%) control (serious AE)
Jaw operation15621.9
18.4–26.1ROR 21.9 · calibrated p 0.001 ✓
18.2 EB05 15.9 · IC025 +3.8
3/3 methods agree
Reporting / coding artifactserious n=155NCT01575834: 1/3,581 (0.0%) on Denosumab (serious AE)
Jaw disorder94921.4
20.0–23.0ROR 21.5 · calibrated p 0.001 ✓
17.9 EB05 16.9 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=445not reported in cached trials
Pathological fracture82520.0
18.6–21.6ROR 20.1 · calibrated p 0.002 ✓
16.9 EB05 16.0 · IC025 +4.0
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=822not reported in cached trials
Abscess jaw16218.8
15.9–22.3ROR 18.9 · calibrated p 0.003 ✓
16.0 EB05 14.0 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=161NCT00089791: 2/3,886 (0.1%) on Denosumab (serious AE)
Dental fistula6218.0
13.7–23.5ROR 18.0 · calibrated p 0.004 ✓
15.3 EB05 12.3 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=62 · 100% cliniciannot reported in cached trials
Delusion of grandeur6517.5
13.5–22.8ROR 17.6 · calibrated p 0.004 ✓
15.0 EB05 12.1 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=65 · ♀ 0% (drug 84%) · 100% cliniciannot reported in cached trials
Loose tooth44516.5
14.9–18.2ROR 16.5 · calibrated p 0.005 ✓
14.3 EB05 13.2 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=269not reported in cached trials
Osteoporotic fracture26016.1
14.1–18.4ROR 16.1 · calibrated p 0.005 ✓
14.0 EB05 12.6 · IC025 +3.6
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious n=260not reported in cached trials
Blood calcium abnormal22216.0
13.9–18.4ROR 16.0 · calibrated p 0.006 ✓
13.9 EB05 12.4 · IC025 +3.5
3/3 methods agree
Lab value / disease markerserious n=109not reported in cached trials
Tooth extraction1,57414.9
14.2–15.8ROR 15.1 · calibrated p 0.007 ✓
13.2 EB05 12.6 · IC025 +3.6
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 11.2not reported in cached trials
Spinal deformity21314.8
12.9–17.1ROR 14.9 · calibrated p 0.008 ✓
13.0 EB05 11.6 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=189 · 74% consumernot reported in cached trials
Endodontic procedure30814.2
12.6–16.0ROR 14.3 · calibrated p 0.009 ✓
12.6 EB05 11.4 · IC025 +3.4
3/3 methods agree
Reporting / coding artifactserious n=125not reported in cached trials
Traumatic fracture8713.8
11.0–17.2ROR 13.8 · calibrated p 0.011 ✓
12.1 EB05 10.1 · IC025 +3.2
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=86 · 100% cliniciannot reported in cached trials
Dental operation27313.0
11.5–14.7ROR 13.0 · calibrated p 0.013 ✓
11.6 EB05 10.5 · IC025 +3.3
3/3 methods agree
Reporting / coding artifactserious n=178not reported in cached trials
Sequestrectomy7312.6
9.9–16.0ROR 12.6 · calibrated p 0.015 ✓
11.1 EB05 9.0 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=73 · 100% cliniciannot reported in cached trials
Metastases to bone1,76312.5
11.9–13.1ROR 12.6 · calibrated p 0.014 ✓
11.2 EB05 10.8 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious PRR 12.0NCT00089791: 1/3,886 (0.0%) on Denosumab; 1/3,876 (0.0%) control (serious AE)
Blood alkaline phosphatase decreased9912.0
9.7–14.7ROR 12.0 · calibrated p 0.018 ✓
10.6 EB05 8.9 · IC025 +3.0
3/3 methods agree
Lab value / disease marker100% cliniciannot reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Osteonecrosis9,34020.019.5–20.4signal
Fall / fracture9,3342.62.5–2.6signal
Neutropenia / agranulocytosis2,7191.11.1–1.2raised
Anaemia3,0351.11.0–1.1raised
Serious infection7,6621.01.0–1.1raised
Tendon disorder3711.00.9–1.1no difference
Interstitial lung disease8961.00.9–1.0no difference
Thrombocytopenia1,8590.90.8–0.9lower than other drugs
Malignancy3,1120.90.8–0.9lower than other drugs
Arrhythmia / qt1,5200.80.8–0.9lower than other drugs
Hyponatraemia6090.80.7–0.9lower than other drugs
Opportunistic infection9910.80.7–0.8lower than other drugs
Venous thromboembolism1,5150.70.7–0.8lower than other drugs
Heart failure1,2300.70.7–0.8lower than other drugs
Stroke1,5350.60.6–0.7lower than other drugs
Kidney injury2,7550.60.6–0.6lower than other drugs

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Denosumab as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (8 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Off label use (used outside approved label)36,7164.6
4.5–4.6ROR 5.4 · calibrated p 0.200
4.4 EB05 4.4 · IC025 +2.1
3/3 methods agree
Reporting / coding artifactage-adj. PRR 4.4 · serious PRR 0.9 · 91% cliniciannot reported in cached trials
Death20,3532.5
2.5–2.5ROR 2.7 · calibrated p 0.746
2.5 EB05 2.4 · IC025 +1.3
3/3 methods agree
Outcome field, not a reaction
boxed warning mentions mortality
age-adj. PRR 2.2 · serious PRR 2.6NCT00089791: 1/3,886 (0.0%) on Denosumab; 2/3,876 (0.1%) control (serious AE)
Arthralgia (joint pain)8,9122.3
2.2–2.3ROR 2.3 · calibrated p 0.891
2.2 EB05 2.2 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.5 · serious PRR 2.1NCT00089791: 15/3,886 (0.4%) on Denosumab; 10/3,876 (0.3%) control (serious AE)
Osteonecrosis of jaw (jawbone death)8,64555.2
53.7–56.6ROR 57.6 · calibrated p 5e-6 ✓
36.1 EB05 35.5 · IC025 +5.1
3/3 methods agree
Labeled — boxed warning
synonym match
serious PRR 38.3NCT00089791: 2/3,886 (0.1%) on Denosumab; 1/3,876 (0.0%) control (serious AE)
Pain in extremity7,0312.5
2.5–2.6ROR 2.6 · calibrated p 0.783
2.5 EB05 2.4 · IC025 +1.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.5 · serious PRR 2.3NCT00089791: 3/3,886 (0.1%) on Denosumab (serious AE)
Pain6,9611.2
1.2–1.2ROR 1.2 · calibrated p 0.431
1.2 EB05 1.2 · IC025 +0.2Labeled — boxed warning
exact term
age-adj. PRR 1.5 · serious PRR 1.1NCT00089791: 8/3,886 (0.2%) on Denosumab; 6/3,876 (0.2%) control (serious AE)
Back pain6,9283.2
3.1–3.2ROR 3.2 · calibrated p 0.552
3.1 EB05 3.0 · IC025 +1.6
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 3.1 · serious PRR 2.8NCT00089791: 20/3,886 (0.5%) on Denosumab; 20/3,876 (0.5%) control (serious AE)
Nausea5,4840.7
0.7–0.7ROR 0.7 · calibrated p 0.137
0.7 EB05 0.7 · IC025 -0.5
PRR-only: not supported by EBGM or IC
Not in label — unassessedage-adj. PRR 0.8 · serious PRR 1.0NCT00089791: 5/3,886 (0.1%) on Denosumab; 5/3,876 (0.1%) control (serious AE)
Diarrhoea (diarrhea)5,3380.9
0.8–0.9ROR 0.9 · calibrated p 0.218
0.9 EB05 0.8 · IC025 -0.3
PRR-only: not supported by EBGM or IC
Not in label — unassessedage-adj. PRR 0.8 · serious PRR 1.1NCT00089791: 6/3,886 (0.2%) on Denosumab; 8/3,876 (0.2%) control (serious AE)
Fall5,2271.6
1.6–1.7ROR 1.7 · calibrated p 0.747
1.6 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.8NCT00089791: 16/3,886 (0.4%) on Denosumab; 18/3,876 (0.5%) control (serious AE)
Rash4,3421.0
1.0–1.1ROR 1.0 · calibrated p 0.335
1.0 EB05 1.0 · IC025 +0.0Labeled adverse reaction
exact term
age-adj. PRR 1.1 · serious PRR 1.1NCT00089791: 1/3,876 (0.0%) control (serious AE)
Myalgia (muscle pain)4,2312.6
2.6–2.7ROR 2.7 · calibrated p 0.744
2.6 EB05 2.5 · IC025 +1.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.5 · serious PRR 2.1NCT00089791: 1/3,886 (0.0%) on Denosumab (serious AE)
Asthenia (weakness)4,0841.1
1.1–1.2ROR 1.1 · calibrated p 0.396
1.1 EB05 1.1 · IC025 +0.1Labeled adverse reaction
exact term
age-adj. PRR 1.0 · serious PRR 1.3NCT00089791: 4/3,886 (0.1%) on Denosumab (serious AE)
Bone pain4,0437.6
7.4–7.9ROR 7.8 · calibrated p 0.072
7.2 EB05 7.0 · IC025 +2.8
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 7.2 · serious PRR 6.1NCT00089791: 4/3,886 (0.1%) on Denosumab; 1/3,876 (0.0%) control (serious AE)

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Denosumab ↔ Osteonecrosis of the jaw.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Denosumab?

In FDA FAERS, the most frequently co-reported reaction terms for Denosumab are arthralgia, osteonecrosis of jaw, fatigue, pain in extremity, pain, back pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Denosumab have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE • Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration.

Do FAERS signals prove that Denosumab causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.